A study on preventive effect of cilostazol against deterioration of symptoms in acute stage of lacunar infarctions

A study on preventive effect of cilostazol against deterioration of symptoms in acute stage of lacunar infarctions - A study on efficacy for cilostazol for acute stage of lacunar infarctions

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000454

Enrollment

Registered

2006-08-01

Start date

2006-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke

Interventions

administered aspirin of 200mg orally for 14days administered aspirin of 200mg and cilostazol of 200mg orally for 14days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients admitted within 48hours from onset of lacunar infarction modified Rankin Scale less than grade 4 on admission

Exclusion criteria

Exclusion criteria: patients with active bleeding or bleeding tendency chronic heart falure peptic ulcer anemia leukocytopenia thrombocytopenia liver dysfunction renal dysfunction neoplastic disorders allergy to aspirin or cilostazol asthma caused by aspirin patients taking antiplatelet drugs, anticoagulants or NSAIDS

Design outcomes

Primary

Measure	Time frame
Activity of Daily Living of 14days after onset which is assessed by modified Rankin Scale and Barthel Index	—

Secondary

Measure	Time frame
NIHSS: 7 and 14days after the admission JSS: 7 and 14days after the admission JSS-M: 7 and 14days after the admission Barthel Index: 7 and 14days after the admission	—

Countries

Japan

Contacts

Public ContactYasuhiro Ishibashi

Iwate Medical University Department of Neurology

yasubasi@iwate-med.ac.jp019-651-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026